BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 8102501)

  • 1. [Resistance to cytostatic agents in patients with refractory multiple myeloma and possible ways to control it].
    Adam Z; Vorlícek J
    Vnitr Lek; 1993 Apr; 39(4):401-7. PubMed ID: 8102501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.
    Dalton WS; Grogan TM; Meltzer PS; Scheper RJ; Durie BG; Taylor CW; Miller TP; Salmon SE
    J Clin Oncol; 1989 Apr; 7(4):415-24. PubMed ID: 2564428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of P-glycoprotein in drug-resistant hematologic malignancies.
    Dalton WS; Grogan TM; Miller TP
    Cancer Treat Res; 1991; 57():187-208. PubMed ID: 1686717
    [No Abstract]   [Full Text] [Related]  

  • 4. In vitro evaluation of chemosensitizers for clinical reversal of P-glycoprotein-associated Taxol resistance.
    Lehnert M; Emerson S; Dalton WS; de Giuli R; Salmon SE
    J Natl Cancer Inst Monogr; 1993; (15):63-7. PubMed ID: 7912531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells.
    Sonneveld P; Schoester M; de Leeuw K
    J Clin Oncol; 1994 Aug; 12(8):1584-91. PubMed ID: 7518859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trials of agents that reverse multidrug-resistance.
    Gottesman MM; Pastan I
    J Clin Oncol; 1989 Apr; 7(4):409-11. PubMed ID: 2564427
    [No Abstract]   [Full Text] [Related]  

  • 7. p170-dependent multidrug resistance. Restoring full sensitivity to idarubicin with verapamil and cyclosporin A derivatives.
    Michieli M; Damiani D; Michelutti A; Melli C; Russo D; Fanin R; Baccarani M
    Haematologica; 1994; 79(2):119-26. PubMed ID: 7914881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A non-P-glycoprotein-mediated mechanism of vincristine transport which is affected by resistance modifiers and present in chemosensitive cells.
    Gruber A; Larsson R; Nygren P; Björkholm M; Peterson C
    Leukemia; 1994 Jun; 8(6):985-9. PubMed ID: 7911547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of reversal of daunorubicin resistance in HL60/AR cells by cyclosporin A.
    Gollapudi S; Gupta S
    Anticancer Res; 1992; 12(6B):2127-32. PubMed ID: 1363515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug resistance in multiple myeloma.
    Sonneveld P; Lokhorst HM; Vossebeld P
    Semin Hematol; 1997 Oct; 34(4 Suppl 5):34-9. PubMed ID: 9408959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P-glycoprotein expression and in vitro reversion of doxorubicin resistance by verapamil in clinical specimens from acute leukaemia and myeloma.
    Solary E; Bidan JM; Calvo F; Chauffert B; Caillot D; Mugneret F; Gauville C; Tsuruo T; Carli PM; Guy H
    Leukemia; 1991 Jul; 5(7):592-7. PubMed ID: 1677057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical multi-drug resistance (MDR): low sensitivity of a P-glycoprotein-expressing human T lymphoblastoid MDR cell line to classical P-glycoprotein-directed resistance-modulating agents.
    Jachez B; Loor F
    Anticancer Drugs; 1993 Dec; 4(6):605-15. PubMed ID: 7905300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
    Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM
    Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
    Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
    Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tumor resistance to multiple antineoplastic agents mediated by glycoprotein P: from the laboratory to the clinical field].
    González-Manzano R
    Med Clin (Barc); 1994 Apr; 102(13):506-15. PubMed ID: 7911549
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug resistance in multiple myeloma.
    Sonneveld P
    Pathol Biol (Paris); 1999 Feb; 47(2):182-7. PubMed ID: 10192886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to tetracycline, a hydrophilic antibiotic, is mediated by P-glycoprotein in human multidrug-resistant cells.
    Kavallaris M; Madafiglio J; Norris MD; Haber M
    Biochem Biophys Res Commun; 1993 Jan; 190(1):79-85. PubMed ID: 8093660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to the chemosensitizer verapamil in a multi-drug-resistant (MDR) human multiple myeloma cell line.
    Abbaszadegan MR; Foley NE; Gleason-Guzman MC; Dalton WS
    Int J Cancer; 1996 May; 66(4):506-14. PubMed ID: 8635866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The multidrug-resistance modifiers verapamil, cyclosporine A and tamoxifen induce an intracellular acidification in colon carcinoma cell lines in vitro.
    Hamilton G; Cosentini EP; Teleky B; Koperna T; Zacheri J; Riegler M; Feil W; Schiessel R; Wenzi E
    Anticancer Res; 1993; 13(6A):2059-63. PubMed ID: 7905252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-glycoprotein expression and activity of resistance modifying agents in primary cultures of human renal and adrenocortical carcinoma cells.
    Fridborg H; Larsson R; Juhlin C; Rastad J; Akerström G; Backlin K; Nygren P
    Anticancer Res; 1994; 14(3A):1009-16. PubMed ID: 7915506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.